Clinical trial outcome of anti-tumour necrosis factor alpha therapy in rheumatic arthritis

Cytokine

Volumn 28, Issue 4-5, 2004, Pages 158-161

  Choy, Ernest ^a  

^a 2nd Fl Weston Educ Ctr GKT S   (United States)

Author keywords

Rheumatoid arthritis; TNF treatment

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

BONE RADIOGRAPHY; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DEMYELINATION; DRUG APPROVAL; DRUG COATING; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; HUMAN; INFECTION RISK; INJECTION PAIN; NONHODGKIN LYMPHOMA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; TUBERCULOSIS; UNITED KINGDOM;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; HUMANS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 9644284330     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2004.07.009     Document Type: Conference Paper

References (21)

1. D.L. Scott, D.P. Symmons, B.L. Coulton, and A.J. Popert Long-term outcome of treating rheumatoid arthritis: results after 20 years Lancet 1 1987 1108 1111
2. F. Wolfe, D.M. Mitchell, J.T. Sibley, J.F. Fries, D.A. Bloch, and C.A. Williams The mortality of rheumatoid arthritis Arthritis Rheum 37 1994 481 494
3. L. Tissi, M. Puliti, R. Barluzzi, G. Orefici, C. von Hunolstein, and F. Bistoni Role of tumor necrosis factor alpha, interleukin-1beta, and interleukin-6 in a mouse model of group B streptococcal arthritis Infect Immun 67 1999 4545 4550
4. E. McIntosh The cost of rheumatoid arthritis Br J Rheumatol 35 1996 781 790
5. E. Yelin, and L.A. Wanke An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline Arthritis Rheum 42 1999 1209 1218
6. L. Iannuzzi, N. Dawson, N. Zein, and I. Kushner Does drug therapy slow radiographic deterioration in rheumatoid arthritis? N Engl J Med 309 1983 1023 1028
7. P. Miossec Pro- and antiinflammatory cytokine balance in rheumatoid arthritis [Review] [16 refs]. Clin Exp Rheumatol 13 Suppl 12 1995 S13 S16
8. A.J. Gearing, P. Beckett, M. Christodoulou, M. Churchill, J. Clements, and A.H. Davidson Processing of tumour necrosis factor-alpha precursor by metalloproteinases Nature 370 1994 555 557
9. M. Feldmann, F.M. Brennan, and R.N. Maini Role of cytokines in rheumatoid arthritis [Review] [226 refs]. Annu Rev Immunol 14 1996 397 440
10. J. Keffer, L. Probert, H. Cazlaris, S. Georgopoulos, E. Kaslaris, and D. Kioussis Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis EMBO J 10 1991 4025 4031
11. M.J. Elliott, R.N. Maini, M. Feldmann, J.R. Kalden, C. Antoni, and J.S. Smolen Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis Lancet 344 1994 1105 1110
12. R.N. Maini, F.C. Breedveld, J.R. Kalden, J.S. Smolen, D. Davis, and J.D. Macfarlane Therapeutic efficacy of multiple intravenous infusions of anti-tumour necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis Arthritis Rheum 41 1998 1552 1563
13. P.E. Lipsky, D.M. van der Heijde, E.W. St Clair, D.E. Furst, F.C. Breedveld, and J.R. Kalden Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group [see comments] N Engl J Med 343 2000 1594 1602
14. L.W. Moreland, S.W. Baumgartner, M.H. Schiff, E.A. Tindall, R.M. Fleischmann, and A.L. Weaver Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein N Engl J Med 337 1997 141 147
15. D.T. Felson, J.J. Anderson, M. Boers, C. Bombardier, D. Furst, and C. Goldsmith American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis Arthritis Rheum 38 1995 727 735
16. L.W. Moreland, M.H. Schiff, S.W. Baumgartner, E.A. Tindall, R.M. Fleischmann, and K.J. Bulpitt Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial Ann Intern Med 130 1999 478 486
17. M.E. Weinblatt, J.M. Kremer, A.D. Bankhurst, K.J. Bulpitt, R.M. Fleischmann, and R.I. Fox A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate [see comments] N Engl J Med 340 1999 253 259
18. J.M. Bathon, R.W. Martin, R.M. Fleischmann, J.R. Tesser, M.H. Schiff, and E.C. Keystone A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis N Engl J Med 343 2000 1586 1593
19. T. Matsuda, and T. Hirano Establishment of the ELISA for murine soluble gp130, a signal transducer for the IL-6 family cytokine, and its detection in the ascitic fluids of tumor-bearing mice Biochem Biophys Res Commun 202 1994 637 642
20. K. Nakajima, T. Kusafuka, T. Takeda, Y. Fujitani, K. Nakae, and T. Hirano Identification of a novel interleukin-6 response element containing an Ets-binding site and a CRE-like site in the junB promoter Mol Cell Biol 13 1993 3027 3041
21. K. Yoshizaki, N. Nishimoto, M. Mihara, and T. Kishimoto Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody [Review] [71 refs] Springer Semin Immunopathol 20 1998 247 259